Bausch added to South Dakota Biotech board
Christoph Bausch, chief scientific officer of SAB Biotherapeutics, has been named to the board of directors of South Dakota Biotech, the state affiliate of the international BIO organization.
Bausch replaces SAB president and CEO Eddie Sullivan, who helped found the association in 2006 and has served on the board ever since.
“It has been gratifying to see South Dakota Biotech grow into a tremendous advocate, resource and connector for our growing industry,” Sullivan said.
“I look forward to staying highly involved and know Christoph will be a great addition to the board. He recently led a thorough evaluation of the state of biotechnology in South Dakota, and having him on the board will assist in implementing the ideas and recommendations found in his report as well as the overall growth of the association.”
Prior to SAB, Bausch served in several business development positions for global biorefining leader, POET, LLC, and worked in research and commercialization for Fortune 500 life science company Sigma-Aldrich.